Opdyta 100 mg Injection 1's

Opdyta 100 mg Injection 1's is an anti-cancer medicine used in the treatment of Melanoma in combination with ipilimumab and other cancers in adults. Melanoma is a severe form of skin cancer that spreads primary melanoma cells to distant organs such as lymph nodes, lungs, liver, brain, and bones. This medicine is used in treating advanced renal cell carcinoma, hepatocellular carcinoma, colorectal cancer, metastatic non-small cell lung cancer, metastatic melanoma, gastric cancer, classical Hodgkin’s disease, urothelial carcinoma, malignant pleural mesothelioma and head and neck cancer.

Opdyta 100 mg Injection 1's contains Nivolumab, which belongs to the class of monoclonal antibody. It works by inhibiting the action of a programmed death receptor-1 (PD-1), thereby stopping the abnormal growth of cancer cells.

Opdyta 100 mg Injection 1's may cause certain side effects such as diarrhoea, nausea, vomiting, tiredness, itching, rash, headache, fever, shortness of breath, muscle/joint pain, loss of appetite and injection site reactions. Inform your doctor if any of these side effects persist for longer. Opdyta 100 mg Injection 1's will be administered by an oncologist trained in administering anti-cancer agents. 

Avoid receiving Opdyta 100 mg Injection 1's and inform your doctor if you are allergic to it or any other components of it. Before taking Opdyta 100 mg Injection 1's, tell your doctor if you have/had liver or kidney disease, autoimmune disorders such as ulcerative colitis or Crohn's disease, a history of organ transplants, received an allogeneic stem cell transplant, or had radiation treatment to the chest. This medicine is known to cause embryo-fetal toxicity. Hence, it is not recommended for use in pregnancy. Avoid breastfeeding while taking this Opdyta 100 mg Injection 1's.

Opdyta 100 mg Injection 1's contains Nivolumab, which is used in the treatment of different types of cancers. It works by inhibiting the action of a programmed death receptor-1 (PD-1) that causes the multiplication of cancerous cells. This helps stop the abnormal growth of cancer cells and thus reduce the further spread to other body parts.

To treat your condition effectually, continue receiving Opdyta 100 mg Injection 1's for the period that your doctor has prescribed. Opdyta 100 mg Injection 1's may cause severe immune-mediated adverse reactions (IMAR) such as immune-mediated colitis, hepatitis, hepatotoxicity, nephritis, endocrinopathies, pneumonitis, complications of allogeneic Hematopoietic Stem Cell Transplantation (allo HSCT) and dermatologic reactions. It may also cause infusion-related reactions in some patients. Therefore, caution should be exercised if you have/had liver or kidney disease, any history of organ transplant, gastrointestinal disorders, myasthenia gravis, received a stem cell transplant that uses donor stem cells (allogeneic), undergone radiation treatment to the chest and autoimmune disorders such as ulcerative colitis, or Crohn’s disease while receiving Opdyta 100 mg Injection 1's. Discontinue the treatment if any severe infusion reactions occur. Inform your doctor if you are pregnant or are planning to become pregnant before starting the treatment, as this medicine is known to cause embryo-fetal toxicity. Breastfeeding should be discontinued in nursing mothers during the treatment as it passes into breast milk and may cause a possible risk to the infant. This medicine is not recommended for use in children below 12 years of age as the safety and efficacy are not established. 

• Your doctor may suggest periodic liver function tests, kidney function tests, and lung function tests to monitor the function of the liver, kidney and lungs due to the use of Opdyta 100 mg Injection 1's.
• Using contraceptive pills while using Opdyta 100 mg Injection 1's to prevent pregnancy is advised.
• Thyroid function and adrenocorticotropic hormone levels will be monitored during treatment to avoid any life-threatening side effects.